Archive for March, 2012

Divided FDA Advisory Committee Votes to Require Cardiovascular Testing for New Obesity Drugs

March 29, 2012 — March 29, 21012 — A panel of experts at the FDA voted 17-6 in favor of requiring all new obesity drugs seeking approval to provide phase 2 or 3 safety data ruling out excess cardiovascular risk, even if the drug does not appear to have a cardiovascular profile.